Rituximab and Ocrelizumab in Serum With Multiple Sclerosis
Launched by HAUKELAND UNIVERSITY HOSPITAL · Oct 28, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, called ROS-MS, is looking at how two medications, rituximab and ocrelizumab, can be used to create personalized treatments for people with relapsing-remitting multiple sclerosis (MS). This means the study wants to understand how these drugs can be tailored to work best for individual patients, based on their specific needs. The trial is currently recruiting participants who are already part of a larger study known as OVERLORD-MS.
To join this trial, participants need to be between the ages of 65 and 74 and must be willing to go to the lab at scheduled times to provide blood samples. If someone is not able or willing to do this, they won't be eligible to participate. Those who do take part can expect to help researchers learn more about MS and potentially contribute to better treatment options for themselves and others in the future. This study is an important step towards understanding how to improve care for people living with MS.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Included in OVERLORD-MS (NCT04578639)
- • Willing to attend laboratory for blood sample collection at scheduled time points
- Exclusion criteria:
- • \* Not willing to attend laboratory for blood sample collection at scheduled time points
About Haukeland University Hospital
Haukeland University Hospital, located in Bergen, Norway, is a leading academic medical center renowned for its commitment to innovative research and high-quality patient care. As a prominent clinical trial sponsor, the hospital leverages its extensive expertise in various medical fields to facilitate cutting-edge clinical studies that aim to advance healthcare outcomes. With a multidisciplinary team of healthcare professionals and researchers, Haukeland University Hospital fosters collaboration and knowledge exchange, ensuring that trials are conducted with the highest standards of ethics, safety, and scientific rigor. Its strategic focus on translational research enhances the bridge between laboratory discoveries and real-world applications, contributing to the global body of medical knowledge.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bergen, Vestland, Norway
Patients applied
Trial Officials
Trond T. Serkland, M.D.
Principal Investigator
Haukeland University Hospital
Silje Skrede, M.D., PhD
Study Director
University of Bergen
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported